Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma

Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma

Abstract In recent years, the use of monoclonal antibodies directed against interleukin-5 (anti-IL-5) and its receptor alpha (anti-IL-5R) has proven to be an effective therapeutic option for patients with severe asthma by reducing the number of eosinophils, which may promote disease remission. This...

Full description

Saved in:
Bibliographic Details
Main Authors: Anaiza Odalis Villalobos Alfaro, Haydee Carolina Gutiérrez Vargas, Juan Manuel Díaz, Jonathan Alvarez Pinto, Diana Cristina García Cambero, Eduardo Hernandez Cuellar, Julio Augusto Palma Zapata, Alondra Esthefanía Llamas Domínguez, Juliana Palma Zapata, Silvia Denise Ponce-Campos
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Asthma
Anti-IL-5
Anti-IL5R
ACQ5
Online Access:https://doi.org/10.1186/s13223-025-00979-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13223-025-00979-y

Similar Items